))
First-line targeted therapy for axial spondyloarthritis
Manage episode 480132987 series 3610272
Saturday, May 3 is World AS Day – an annual day dedicated to people living with axial spondyloarthritis (axSpA).
AxSpA is a chronic rheumatic disease that can cause severe pain and stiffness in the lower back, hips and buttocks and if left untreated can cause permanent damage to your spine. The pain often gets worse with rest and often appears before the age of 40.
In honour of #WorldASDay2025, this episode of #ArthritisAtHome will highlight the #CRArthritis interview with Dr. Water Maksymowych, a Professor in the Faculty of Medicine and Dentistry at the Unversity of Alberta. He is co-founder and principal investigator the Spondyloarthritis Research Consortium of Canada (SPARCC).
Dr. Maksymowych discusses his presentation during the Controversies in Rheumatology session at this year’s meeting. The presentation focuses on the complexities of first-line targeted therapies for axial spondyloarthritis (axSpA). He outlines how advanced therapies work differently in managing axSpA and what factors rheumatologists consider when deciding which of these medications should be used first for a patient with axSpA. He concludes by recommending how patients can work with their health care providers to ensure they receive the most effective treatment for their axSpA.
Additional learning resource
140 episodes
Share
